.png){kind=icon}
Return
Osteosarcoma
.png){kind=icon}
PRE
AI
DOI：10.1038/s41572-022-00409-y.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Osteosarcoma is the most common primary malignant tumour of the bone. Osteosarcoma incidence is bimodal, peaking at 18 and 60 years of age, and is slightly more common in males. The key pathophysiological mechanism involves several possible genetic drivers of disease linked to bone formation, causing malignant progression and metastasis. While there have been significant improvements in the outcome of patients with localized disease, with event-free survival outcomes exceeding 60%, in patients with metastatic disease, event-free survival outcomes remain poor at less than 30%. The suspicion of osteosarcoma based on radiographs still requires pathological evaluation of a bone biopsy specimen for definitive diagnosis and CT imaging of the chest should be performed to identify lung nodules. So far, population-based screening and surveillance strategies have not been implemented due to the rarity of osteosarcoma and the lack of reliable markers. Current screening focuses only on groups at high risk such as patients with genetic cancer predisposition syndromes. Management of osteosarcoma requires a multidisciplinary team of paediatric and medical oncologists, orthopaedic and general surgeons, pathologists, radiologists and specialist nurses. Survivors of osteosarcoma require specialized medical follow-up, as curative treatment consisting of chemotherapy and surgery has long-term adverse effects, which also affect the quality of life of patients. The development of osteosarcoma model systems and related research as well as the evaluation of new treatment approaches are ongoing to improve disease outcomes, especially for patients with metastases.
Keywords:
HIGH-GRADE OSTEOSARCOMA
PATIENT-DERIVED XENOGRAFTS
MESENCHYMAL STEM-CELLS
PHASE-II
PREOPERATIVE CHEMOTHERAPY
MURAMYL TRIPEPTIDE
CHILDHOOD-CANCER
HISTOLOGIC RESPONSE
ONCOLOGY-GROUP
BONE SARCOMAS
Journal
N
IF:
60.6
Papers:
648
Citations:
3.8W
Organization
Cited Papers
ShareSaveShareSaveShareSaveShareSaveShareSaveAlternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis.png)
BMC CANCER
OAAI
BMC CANCERIF3.4
OAAIShareSave
View more